Methyllycaconitine (citrate) manufacturers
|
| | Methyllycaconitine (citrate) Basic information |
| Product Name: | Methyllycaconitine (citrate) | | Synonyms: | Methyllycaconitine citrate, 10 mM in DMSO;(10S)-Methyllycaconitine citrate;((3S,6S,6aS,7R,7aR,8S,9R,10S,11aR,12S,12aS,13S,14R)-1-Ethyl-11a,12-dihydroxy-6,8,10,13-tetramethoxydodecahydro-2H-3,6a,12-(epiethane[1,1,2]triyl)-7,9-methanonaphtho[2,3-b]azocin-3(4H)-yl)methyl 2-((S)-3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate 2-hydroxypropane-1,2,3-tricarboxylate(1:1);Methyllycaconitine citrate (1:1) | | CAS: | 351344-10-0 | | MF: | C43H58N2O17 | | MW: | 874.93 | | EINECS: | | | Product Categories: | | | Mol File: | 351344-10-0.mol |  |
| | Methyllycaconitine (citrate) Chemical Properties |
| storage temp. | Desiccate at -20°C | | solubility | Water: Soluble | | form | A solid | | color | White to yellow |
| | Methyllycaconitine (citrate) Usage And Synthesis |
| Description | Methyllycaconitine (MLA) is an antagonist of α7-containing neuronal nicotinic acetylcholine receptors (nAChRs; Ki = 1.4 nM). It is less effective at other nAChRs. MLA is used to selectively evaluate the role of α7-containing nAChRs in signaling pathways. | | Uses | Methyllycaconitine citrate is a specific antagonist of α7 neuronal nicotinic acetylcholine receptor (α7nAChR) with blood-brain barrier permeability. | | in vivo | Methyllycaconitine citrate (MLA) (6 mg/kg) given alone intraperitoneally does not cause climbing behavior when compare with the saline group. Pretreatment with Methyllycaconitine citrate significantly inhibits methamphetamine (METH)-induced climbing behavior, by about 50%. Methyllycaconitine citrate does not modify either basal locomotor activity or METH-induced hyperlocomotion. The METH-induced depletion of dopamine neuron terminals is attenuated in mice pretreated with Methyllycaconitine citrate (250±43 fmol/mg, n=7). A direct effect of Methyllycaconitine citrate on body temperature is ruled out because Methyllycaconitine citrate does not affect basal body temperature (37.0±0.5°C, n=5) or reduce the METH-induced hyperthermia (38.2±0.4°C, n=6, MLA+METH group, n.s. versus METH group)[1]. | | storage | Store at -20°C | | References | [1] Zheng X, et al. Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. PLoS One. 2014 Oct 31;9(10):e111536. DOI:10.1371/journal.pone.0111536
[2] Escubedo E, et al. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors. J Pharmacol Exp Ther. 2005 Nov;315(2):658-67. DOI:10.1124/jpet.105.089748
[3] Lockman PR, et al. Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine. J Neurochem. 2005 Jul;94(1):37-44. DOI:10.1111/j.1471-4159.2005.03162.x |
| | Methyllycaconitine (citrate) Preparation Products And Raw materials |
|